Sugi Predict

Sugi Predict / Compounds / SCHEMBL196962

SCHEMBL196962

SCHEMBL196962

CCCOc1cccc(Cl)c1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.68
▸ LMNA P02545 1/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ HTT P42858 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ KCNH2 Q12809 1/20 0.58
▸ DRD2 P14416 1/20 0.56
▸ DRD4 P21917 1/20 0.56
▸ KDM4E B2RXH2 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ WDR5 P61964 1/20 0.51
▸ HRH3 Q9Y5N1 5/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ FAAH O00519 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL197632 0.90 KMT2A (0.76) KMT2ALMNAMAPK1HTTSMN1; SMN2
SCHEMBL8551026 0.89 KMT2A (0.73) KMT2ALMNAMAPK1HTTSMN1; SMN2
SCHEMBL9808215 0.87 LMNA (0.67) KMT2ALMNAMAPK1HTTSMN1; SMN2
Methyl Alcohol SCHEMBL27541418 0.87 KMT2A (0.71) KMT2ALMNAMAPK1HTTSMN1; SMN2
Dimethylamine SCHEMBL3445328 0.85 KMT2A (0.74) KMT2ALMNAMAPK1HTTSMN1; SMN2
1,3-Dipropoxybenzene SCHEMBL73716 0.85 KMT2A (0.63) KMT2ALMNAMAPK1KDM4ECYP2D6
SCHEMBL315808 0.83 TP53 (0.59) KMT2ALMNAMAPK1HTTSMN1; SMN2
SCHEMBL30167806 0.83 TP53 (0.59) KMT2ALMNAMAPK1HTTSMN1; SMN2
SCHEMBL366495 0.82 HTT (0.57) KMT2ALMNAMAPK1HTTSMN1; SMN2
SCHEMBL19001378 0.82 KMT2A (0.56) KMT2ALMNAMAPK1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105732309-A Chiral preparation method of dapoxetine hydrochloride key intermediate 山东省药学科学院 2016-07-06 — — CN claimed
CN-105445384-A Separating and detecting method for 3-chloro-1-phenyl-1-propanol optical isomers and applications thereof GUANGZHOU REGENEX CORP 2016-03-30 — — CN claimed
CN-103396320-A (S)-3-chloro-N, N-dimethyl-1-phenyl-1-propylamine and method for preparing dapoxetine by using same as intermediate NANJING HAIRONG PHARMACEUTICAL TECHNOLOGY CO LTD 2013-11-20 — — CN claimed
CN-101844966-A Preparation method of 3-chlorobenzene propyl alcohol SHANGHAI ZHONGKANG WEIYE BIOLOG SCIENCE & TECHNOLOGY CO LTD 2010-09-29 — — CN claimed
EP-1635839-B1 BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY ABBOTT HEALTHCARE PRODUCTS BV (NL) 2010-09-01 — — EP claimed
CN-100591649-C Method of preparing R-(+)-3-chlorophenylpropanol TIANDU CHEN 2010-02-24 — — CN claimed
EP-2108012-A2 SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2009-10-14 — — EP claimed
WO-2008099076-A2 SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2008-08-21 — — WO claimed
CN-100402488-C Synthetic method for dapoxetine SHANGHAI MAYAO CHEMICAL TECHNO (CN) 2008-07-16 — — CN claimed
CN-101012147-A Method of preparing R-(+)-3-chlorophenylpropanol CHEN TIANDU (CN) 2007-08-08 — — CN claimed
CN-1821212-A Synthetic method for dapoxetine MAYAO CHEMICAL TECHNOLOGY CO L (CN) 2006-08-23 — — CN claimed
EP-3632892-B1 METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2024-07-31 — — EP disclosed
CN-110799490-B 3-arylpropionamide compound and method for producing 3-arylpropionate compound 住友化学株式会社 2023-05-02 — — CN disclosed
US-11028056-B2 Method for producing 3-arylpropionamide compound and 3-arylpropionic acid ester compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-06-08 — — US disclosed
US-20200223871-A1 Arginase Inhibitors and Methods of Use ASTRAZENECA AB (SE) 2020-07-16 — — US disclosed
CN-1086387-C N- (aryloxyalkyl) heteroarylpiperidines and heteroarylpiperazines, their preparation and their use as pharmaceuticals HOECHST MARION ROUSSEL INC (US) 2002-06-19 — — CN disclosed
WO-2001090037-A1 METHOD FOR PRODUCING ACYLATED PHENOL ETHERS BAYER AKTIENGESELLSCHAFT (DE) 2001-11-29 — — WO disclosed
CN-1048037-A N- (aryloxyalkyl) heteroarylpiperidines and heteroarylpiperazines, their preparation and their use as pharmaceuticals HOECHST ROUSSEL PHARMA (US) 1990-12-26 — — CN disclosed
CN-1007153-B PREPN. OF BENZOTHIOPHENES AND BENZOFURANS HAVING ANTIALLERGY ACTIVITY WARNER LAMBERT CO (US) 1990-03-14 — — CN disclosed
CN-85109587-A Have the new benzothiophene kind of antiallergic activity and the preparation method of benzofuran compounds — 1986-12-17 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200223871-A1 Arginase Inhibitors and Methods of Use ARG1, ARG2, NOS2 KMT2A 1795/4885LMNA 3655/4885MAPK1 671/4885
US-11028056-B2 Method for producing 3-arylpropionamide compound and 3-arylpropionic acid ester compound AADAC, DDT, NAT1 KMT2A 861/4885LMNA 4146/4885MAPK1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.